UroGen Pharma (URGN) PT Raised to $50 at Oppenheimer

Oppenheimer analyst Leland Gershell raised the price target on UroGen Pharma (NASDAQ: URGN) to $50.00 (from $40.00) while maintaining a Outperform rating.

The analyst comments "We increase our sales estimates following recent conversations with management. We now project 2026-28E Zusduri sales of $210M, $448M, and $648M vs. $204M, $411M, and $595M, respectively. For the three remaining 2026 quarters to be reported, we now project Zus sales of $43.0M, $60.0M, and $78.0M vs. consensus (Visible Alpha) estimates of $38.5M, $48.1M, and $54.5M, respectively. We expect URGN to report 2Q26 financials in early August. We see continued outperformance following the recent run (shares up 110% since April 1 vs. +22% XBI) and raise our PT to $50 (from $40)."

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• UBS Reiterates Buy Rating on Hilton Worldwide (HLT)
• Phillips 66, Marathon Merger Talks Collapsed - Semafor